Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Inhalers and how they work

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

COPD inhalers come in three active ingredients, combined in various ways. Knowing which of the three is in your device tells you most of what it does.

The newest part of the decision is whether an inhaled steroid belongs in the mix, and that now depends partly on a blood test.

Related pages: COPD (chronic lung disease)

The bottom line

What we know
  • Short-acting relievers are for immediate symptoms.
  • Long-acting bronchodilators, LAMA and LABA, are the maintenance foundation.
  • Inhaled steroids help some people with COPD and raise pneumonia risk in others.
  • A blood eosinophil count helps predict who benefits from inhaled steroids.
  • Triple therapy combines all three for people with continuing exacerbations.
What is still open
  • The best thresholds for using eosinophils to guide treatment.
  • Who can safely step down from inhaled steroids.
  • Whether any inhaled treatment slows functional decline.

The story, step by step

  1. 1. Relievers ()
  2. 2. The foundation ()
  3. 3. Steroids ()
  4. 4. Triple therapy ()
  5. 5. The other medicines ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

The rescue inhaler

Review of many studies

What happens

Fast, short, as needed.

What the research shows

  • Short-acting beta-agonists such as albuterol or salbutamol relax airway muscle within minutes and last a few hours.
  • Short-acting antimuscarinics such as ipratropium work slightly more slowly and last a little longer.
  • They are used as needed for breathlessness, and everyone with COPD should have one.
  • They relieve symptoms but do nothing about the underlying disease, so they are not a substitute for maintenance treatment.
  • Needing a reliever far more often than usual is one of the early signs of an exacerbation, and is worth tracking.
  • Side effects include tremor and palpitations with beta-agonists, and dry mouth with antimuscarinics.

Why it matters

Reliever use is a useful early-warning signal. A change in how often it is needed usually precedes a flare-up by days.

What's still uncertain

  • How best to track reliever use in practice.
  • Whether smart inhalers that record use improve outcomes.

Read more

Next: The foundation

Part 2 of 5

LAMA and LABA

Review of many studies

What happens

Long-acting, taken every day.

What the research shows

  • Long-acting antimuscarinics, LAMAs, such as tiotropium, umeclidinium and glycopyrronium, work for 12 to 24 hours.
  • Long-acting beta-agonists, LABAs, such as formoterol, salmeterol and vilanterol, relax airway muscle by a different route.
  • Both reduce breathlessness, improve exercise capacity and reduce exacerbations, and combining them works better than either alone.
  • A key benefit is reducing hyperinflation, which is why people often report being able to walk further even when spirometry barely changes.
  • LAMAs appear somewhat more effective than LABAs at preventing exacerbations.
  • They are maintenance treatment and must be taken daily, including on days when breathing feels fine. This is the most common misunderstanding about them.

Why it matters

Maintenance inhalers taken only when symptomatic deliver almost none of their benefit, and this mistake is extremely common.

What's still uncertain

  • The best combination for individual patients.
  • Whether any of these slow the decline in lung function.

Read more

Next: Steroids

Part 3 of 5

When they help, and when they do not

Review of many studies

What happens

Not for everyone, unlike asthma.

What the research shows

  • Inhaled corticosteroids reduce airway inflammation. In asthma they are central; in COPD their role is selective.
  • They reduce exacerbations in people who have frequent ones, and in those with features of asthma overlap.
  • They also increase the risk of pneumonia in COPD, along with oral thrush, hoarseness and bruising.
  • The decision now uses the blood eosinophil count: higher counts predict benefit, and low counts predict little benefit with the same pneumonia risk.
  • They are not used alone in COPD, always in combination with a long-acting bronchodilator.
  • Rinse your mouth after using one, which substantially reduces thrush and hoarseness.

Why it matters

The pneumonia trade-off is the reason inhaled steroids are not given to everyone with COPD, and it is the clearest difference from asthma treatment.

What's still uncertain

  • The best eosinophil thresholds for the decision.
  • Who can safely withdraw inhaled steroids.

Read more

Next: Triple therapy

Part 4 of 5

All three together

Review of many studies

What happens

For continuing exacerbations.

What the research shows

  • Triple therapy combines a LAMA, a LABA and an inhaled corticosteroid, usually in one device.
  • It is used for people who continue to have exacerbations despite dual bronchodilator treatment, particularly with higher eosinophil counts.
  • Trials have shown reduced exacerbations, and some have shown reduced mortality compared with dual therapy.
  • A single device improves adherence compared with taking three separate inhalers.
  • Stepping down from triple therapy is possible in selected people and should be planned rather than improvised, as exacerbations can return.
  • Escalation should follow a review of whether the inhaler is being used correctly, because poor technique is a far more common reason for failure than an inadequate drug.

Why it matters

Before adding a third drug, the useful question is whether the first two are reaching the lungs at all. Often they are not.

What's still uncertain

  • Who can step down safely.
  • Whether the mortality benefit is robust.

Read more

Next: The other medicines

Part 5 of 5

Beyond inhalers

Review of many studies

What happens

A short list, used selectively.

What the research shows

  • Oral corticosteroids are used in short courses for exacerbations, not long term, because prolonged use causes osteoporosis, diabetes, muscle weakness and infection risk.
  • Azithromycin taken long term reduces exacerbations in selected patients, with trade-offs including hearing effects, heart rhythm and antibiotic resistance.
  • Roflumilast reduces exacerbations in severe disease with chronic bronchitis, and commonly causes nausea, diarrhoea and weight loss.
  • Mucolytics such as carbocisteine help some people with persistent sputum.
  • Theophylline is now rarely used, because the margin between effective and toxic doses is narrow.
  • Alpha-1 augmentation therapy is specific to alpha-1 antitrypsin deficiency.
  • Vaccination against influenza, COVID-19, pneumococcus and RSV is part of treatment, because infections drive exacerbations.

Why it matters

Long-term oral steroids are still prescribed for COPD in some places. They are not recommended for maintenance, and the harms accumulate quietly.

What's still uncertain

  • Who benefits most from long-term azithromycin.
  • The role of mucolytics in modern practice.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.